CTI BioPharma Revenue, Profits - CTIC Annual Income Statement

Add to My Stocks
$1.91 $0.03 (1.6%) CTIC stock closing price Sep 19, 2018 (Closing)

Financial statements provide us with a way to gain insights and undertake the fundamental analysis of a company. Checking CTI BioPharma stock price alone is not sufficient. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. Like any other income statement, the CTIC income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a YOY revenue decline of -56.2% when compared to the same period in the past. One also needs to look at CTI BioPharma assets, operating expenses and CTI BioPharma free cash flow. The CTI BioPharma profit and loss statement shows revenue of $25.14M for 2017. Revenue has decreased by -56.2% YOY for CTIC stock.

View revenue and profit details for latest and last 10 financial years.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
CTI BioPharma Revenues or Net Sales
Cost Of Goods Sold (COGS)-1.37M1.94M------3.24M
CTI BioPharma Gross Profit
Research & Development Expense32.86M64.96M76.62M86.45M33.62M62.3M34.9M27.03M30.17M51.65M
Selling General & Admin Expense31.43M40.22M54.21M58.96M42.44M39.18M27.29M48.04M51.46M32.16M
Income Before Depreciation Depletion Amortization-39.51M-49.16M-116.66M-86.23M-41.52M-101.49M-62.19M-74.75M-81.55M-75.62M
Depreciation Depletion Amortization--------5.78M68.18M
Non Operating Income--1.17M-1.99M-6.04M-0.99M-0.13M1.15M-4.68M12.27M49.24M
Interest Expense1.87M2.61M2.1M1.94M1.02M-1.03M2.33M11.15M78.8M
CTI BioPharma Pretax Income
Provision for Income Taxes----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-40.83M-52.95M-120.76M-94.22M-43.54M-101.68M-62.61M-82.83M-95.64M-180.02M
Extraordinary Items & Discontinued Operations----------
CTI BioPharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS36.45M27.95M18.84M14.85M11.42M5.81M3.43M2.28M1.53M-
Average Shares used to compute Basic EPS36.45M27.95M18.84M14.85M11.42M5.81M3.43M2.28M1.53M-
Income Before Nonrecurring Items-40.67M-52.01M-119.42M-93.37M-41.53M-101.37M-73.36M-80.61M-95.66M-251.19M
Income from Nonrecurring Items-----1.22M-11M-2.03M-71.16M
CTI BioPharma Earnings Per Share Basic Net
CTI BioPharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-1.24-1.86-6.50-6.50-4.20-19.80-38.50-65.99-77.98-2837.43
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

CTI BioPharma stock analysis involves checking at least a few of the important things like:

  • Topline: A growing topline, as seen from the CTI BioPharma revenue chart, as isn't the case with CTI BioPharma indicates a sagging business. One needs to compare the YoY topline or sales growth of CTIC stock with its peers like RFL stock and MTEM stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-40.67M for CTI BioPharma for 2017. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the CTIC income statement, one can check the CTI BioPharma historical stock prices to check how the price has moved with time.

CTI BioPharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield